226 related articles for article (PubMed ID: 35380664)
1. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
Dubinsky MC; Magro F; Steinwurz F; Hudesman DP; Kinnucan JA; Ungaro RC; Neurath MF; Kulisek N; Paulissen J; Su C; Ponce de Leon D; Regueiro M
Inflamm Bowel Dis; 2023 Jan; 29(1):51-61. PubMed ID: 35380664
[TBL] [Abstract][Full Text] [Related]
2. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Quirk D; Wang W; Nduaka CI; Mukherjee A; Su C; Sands BE
Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1821-1830.e3. PubMed ID: 33127596
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
[TBL] [Abstract][Full Text] [Related]
6. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a
Rubin DT; Salese L; Cohen M; Kotze PG; Woolcott JC; Su C; Mundayat R; Paulissen J; Torres J; Long MD
Therap Adv Gastroenterol; 2023; 16():17562848231189122. PubMed ID: 37560161
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
Loftus EV; Baumgart DC; Gecse K; Kinnucan JA; Connelly SB; Salese L; Su C; Kwok KK; Woolcott JC; Armuzzi A
Inflamm Bowel Dis; 2023 May; 29(5):744-751. PubMed ID: 35792493
[TBL] [Abstract][Full Text] [Related]
9. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
Biedermann L; Dubinsky MC; Vermeire S; Fellmann M; Gardiner S; Hur P; Mundayat R; Panés J; Rubin DT
Inflamm Bowel Dis; 2023 Sep; 29(9):1370-1379. PubMed ID: 36242764
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Sandborn WJ; Armuzzi A; Liguori G; Irving PM; Sharara AI; Mundayat R; Lawendy N; Woolcott JC; Danese S
Inflamm Bowel Dis; 2022 Sep; 28(9):1338-1347. PubMed ID: 34958359
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
Hudesman DP; Torres J; Salese L; Woolcott JC; Mundayat R; Su C; Mosli MH; Allegretti JR
Patient; 2023 Mar; 16(2):95-103. PubMed ID: 36336750
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Bressler B; Francisconi C; Vermeire S; Lawendy N; Salese L; Sawyerr G; Shi H; Su C; Judd DT; Jones T; Loftus EV
Inflamm Bowel Dis; 2023 Jan; 29(1):27-41. PubMed ID: 36342120
[TBL] [Abstract][Full Text] [Related]
14. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
15. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Farraye FA; Qazi T; Kotze PG; Moore GT; Mundayat R; Lawendy N; Sharma PP; Judd DT
Aliment Pharmacol Ther; 2021 Aug; 54(4):429-440. PubMed ID: 34165201
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
Lee SD; Allegretti JR; Steinwurz F; Connelly SB; Lawendy N; Paulissen J; Gecse KB
BMC Gastroenterol; 2023 Feb; 23(1):34. PubMed ID: 36755231
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
18. Modified Mayo score
Sandborn WJ; Sands BE; Vermeire S; Leung Y; Guo X; Modesto I; Su C; Wang W; Panés J
Therap Adv Gastroenterol; 2022; 15():17562848221136331. PubMed ID: 36506749
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Hanauer S; Panaccione R; Danese S; Cheifetz A; Reinisch W; Higgins PDR; Woodworth DA; Zhang H; Friedman GS; Lawendy N; Quirk D; Nduaka CI; Su C
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):139-147. PubMed ID: 30012431
[TBL] [Abstract][Full Text] [Related]
20. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]